Home
About Us
About Us
Board of Directors
Scientific Advisory Board
Management Team
Careers
For Researchers
Paxalisib
EVT801
Collaborating with Kazia
Publications and Presentations
For Partners
Our Current Partners
What We Are Looking For
For Patients
Accessing Kazia Drug Candidates in Clinical Trials
Accessing Kazia Drug Candidates for Compassionate Use
Resources for Patients
For Investors
Press Releases
ASX Announcements
Delisting from ASX
How to convert unlisted shares to ADSs
SEC Filings
Corporate Presentations
Annual Reports
Financial Reports
AGM
Corporate Governance
Shareholder Services
Media Centre
Overview
Video
Coverage
Contact
Contact Us
Subscribe to email alerts
Heading &
Sub-heading can be edited through HQI
Home
>
Media Centre
>
Coverage
Overview
Video
Coverage
Coverage
2-Dec-2024
BioSpace: Biopharma Takes on Deadly Brain Cancer After Decades of Failure
2-May-2024
Kazia reports successful stage 1 completion of the EVT801 Phase 1 clinical trial in advanced cancer patients
11-Feb-2024
Professor takes big step in fighting cancer which claimed his daughter
23-Dec-2023
Parents of kids with DIPG say funding for trial urgently needed
23-Nov-2023
Kazia provides overview of Paxalisib related presentations from the Society of Neuro-Oncology 2023 Annual Meeting
1-May-2023
Kazia Therapeutics appoints Dr John Friend as new CEO
4-Apr-2023
Kazia Therapeutics to present new pipeline molecule data at AACR 2023
6-Mar-2023
Kazia Therapeutics forms clinical collaboration for Australian Phase 2 study of paxalisib, targeting childhood cancers
28-Feb-2023
Kazia Therapeutics raises A$7 million to fund R&D pipeline
6-Feb-2023
After a successful $4.5 million cap raise and with cancer trial results to come, Kazia is optimistic for 2023
31-Jan-2023
ASX rose 6.2% in January: Aus shares closed the day 0.07% lower
31-Jan-2023
High cost of living causes a fall in retail sales: ASX up 0.22% at noon
17-Jan-2023
Kazia Therapeutics CEO talks $4.5 million capital raise
16-Jan-2023
Kazia Therapeutics raising $4.5 million in placement; launches SPP
20-Dec-2022
Kazia Therapeutics exploring use of lead asset in other cancers: Edison Investment Research
14-Dec-2022
Kazia Therapeutics files patent as it continues to work with QIMT on cancer research
9-Dec-2022
SMH: ‘Waiting for your child to die is not an option’
8-Dec-2022
Kazia Therapeutics’ upcoming top-line data for EVT801 expected to be a share price catalyst: Edison Investment Research
5-Dec-2022
Kazia Therapeutics talks positive pre-clinical data for EVT801
1-Dec-2022
Almost all sectors higher: Aus shares close up 1%
1-Dec-2022
ASX opens to 7-month high after Powells positive news: Aus shares up 0.8%
30-Nov-2022
Kazia Therapeutics welcomes publication of positive pre-clinical data for EVT801 in peer-reviewed cancer research journal
1-Nov-2022
ASX increases slightly ahead of today's interest rate rise: Aus shares 0.3% higher at noon
28-Oct-2022
US tech earnings weighing down Aus tech sector: ASX falls 0.62% at noon
28-Oct-2022
Stocks of the Hour: Kazia Therapeutics, Green Technology Metals, Winsome Resources
28-Oct-2022
Kazia Therapeutics’ (ASX:KZA) paxalisib shows positive signals against preclinical melanoma models
5-Oct-2022
Kazia Therapeutics takes Phase 2 study of paxalisib international; opens two sites in Australia
27-Sep-2022
Stockhead Health and Biotech Investment Guide
8-Aug-2022
Stocks of the Hour: Kazia Therapeutics, Mesoblast, BHP &Oz Minerals
8-Aug-2022
ASX edges lower in morning trading, reporting season kicks off: Aus shares down 0.2% at noon
8-Aug-2022
Kazia Therapeutics gives progress report on GBM AGILE pivotal study for glioblastoma
7-Aug-2022
Kazia Therapeutics' promising data on treatment targeting brain metastases to be presented at conference
11-Jul-2022
Kazia Therapeutics forms new Scientific Advisory Board with world-leading experts in brain cancer
7-Jul-2022
Tech snaps 4-day winning streak, Iron ore miners rebound: ASX closes 0.8% higher
7-Jul-2022
Australia trade surplus hits record high, Chalice Mining soars on discovery: ASX up 0.2% at noon
7-Jul-2022
Stocks of the Hour: Elsight, Kazia Therapeutics, Chalice Mining
6-Jul-2022
Kazia Therapeutics gains US FDA Rare Paediatric Disease Designation for paxalisib in rare form of childhood brain cancer
30-Jun-2022
Kazia Therapeutics continues to make good progress on cancer treatment assets
17-Jun-2022
Kazia Therapeutics secures orphan drug designation for treatment of AT/RT tumours with paxalisib
14-Jun-2022
Stocks of the Hour: Kazia Therapeutics, Westgold Resources &Lake Resources
13-Jun-2022
Kazia Therapeutics welcomes presentation of positive paxalisib data at international symposium
8-Jun-2022
Kazia onto next chapter in Phase 2 brain metastases trial
7-Jun-2022
Kazia Therapeutics’ Phase 2 paxalisib study moves to expansion stage in breast cancer brain metastases cohort
31-May-2022
Kazia Therapeutics’ paxalisib now the subject of multi-drug platform study at the University Hospital, Zurich
11-May-2022
Sector Watch: Healthcare - M&Afever on the cards?
11-May-2022
Nasdaq jumps as Dow falls, Immutep, Antisense, Pushpay, AGL, Star on watch: ASX poised to open lower
5-May-2022
Kazia Therapeutics and its flagship asset have made significant progress against brain cancers: Pitt Street Research
2-May-2022
Kazia Therapeutics wraps up a busy quarter presenting paxalisib data at the AACR annual meeting
25-Apr-2022
Kazia Therapeutics establishes ‘at the market’ equity program
21-Apr-2022
Kazia Therapeutics completes Phase 2 study of glioblastoma drug Paxalisib; data to follow at conference
8-Apr-2022
Kazia Therapeutics encouraged by “promising data” on its cancer pipeline presented at AACR meeting in New Orleans
28-Feb-2022
Kazia Therapeutics initiates Phase II study of paxalisib for newly diagnosed and recurrent glioblastoma
24-Feb-2022
Kazia Therapeutics delivers on plans with two promising assets in human trials
12-Dec-2021
Kazia Therapeutics appoints US-based CFO to assist global market expansion
9-Dec-2021
Kazia Therapeutics' clinical paxalisib data maintains Speculative Buy rating from Bell Potter
3-Dec-2021
Kazia Therapeutics (ASX:KZA) announces positive results for brain cancer drug
3-Dec-2021
ASX up, Berkshire billionaire gives his views on crypto and will BHP benefit from rising iron ore prices?
2-Dec-2021
Kazia Therapeutics releases positive final data from Phase 2 trial of glioblastoma treatment paxalisib, shares up
29-Nov-2021
Kazia Therapeutics expands further in North America with Toronto glioblastoma study
15-Nov-2021
Kazia Therapeutics appoints former Cellectar Biosciences chief medical officer John Friend as new CMO
10-Nov-2021
Kazia Therapeutics welcomes start of PNOC study in childhood brain cancer, first patient enrolled
7-Nov-2021
Kazia Therapeutics marks big step forward as first patient enrols in EVT801 cancer therapy trial
4-Nov-2021
Kazia Therapeutics enrols first patient to phase I clinical trial of EVT801 cancer therapy
28-Oct-2021
Kazia Therapeutics gets boost with ‘buy’ call from Maxim Group and valuation upgrade from Edison
14-Oct-2021
Kazia Therapeutics’ paxalisib program data garners increased target share price of A$2.83 from Edison
14-Sep-2021
Kazia Therapeutics with Proactive at the ASX Small and Mid Cap Conference
2-Sep-2021
Kazia Therapeutics receives full regulatory approval for EVT801 phase 1 study
9-Dec-2020
Kazia Therapeutics (ASX:KZA) see promising data from Phase 1 ovarian cancer trial
27-Apr-2020
Kazia Therapeutics (ASX:KZA) glioblastoma Phase II trial results